The chemical name you provided, **2-(2-oxo-1-benzo[cd]indolyl)-N-(2-oxolanylmethyl)acetamide**, refers to a synthetic molecule that is **not widely studied or documented** in the scientific literature. This means there is **no readily available information on its importance for research**.
**Here's why:**
* **Uncommon Structure:** The molecule contains a unique combination of structural elements, including a benzo[cd]indole ring system and an oxolanylmethyl group. This type of molecule is likely not a naturally occurring compound.
* **Limited Research:** The lack of research on this specific compound suggests it has not been investigated extensively for potential applications or biological activities.
* **Lack of Public Data:** The molecule is not listed in major chemical databases like PubChem or ChemSpider, indicating that there is no readily available data on its properties or potential applications.
**Possible Reasons for Limited Research:**
* **Recent Synthesis:** The molecule may be a newly synthesized compound, and research is still ongoing.
* **Specific Target:** The molecule might be designed for a very specific application that has not yet been published.
* **Lack of Interest:** It's possible that the molecule has been synthesized but not found to be particularly promising for further investigation.
**To find out more about the importance of this molecule for research, you would need to:**
1. **Contact the original researchers who synthesized it:** If you know who synthesized the molecule, you can reach out to them directly for information about its research applications.
2. **Search for recent publications:** While there might not be much information currently available, there might be recent research papers that are not yet indexed in the main databases.
3. **Contact experts in relevant fields:** Reach out to researchers specializing in organic chemistry, medicinal chemistry, or drug discovery to see if they are aware of any research on this molecule.
Remember, just because a molecule is not well-known doesn't mean it's not important for research. It could be a promising candidate for future applications in various fields.
| ID Source | ID |
|---|---|
| PubMed CID | 2947859 |
| CHEMBL ID | 1421291 |
| CHEBI ID | 107605 |
| Synonym |
|---|
| MLS000063248 |
| 2-(2-oxobenzo[cd]indol-1(2h)-yl)-n-(tetrahydro-2-furanylmethyl)acetamide |
| smr000074826 |
| MLS000115114 |
| CHEBI:107605 |
| AKOS000591846 |
| 2-(2-oxobenzo[cd]indol-1(2h)-yl)-n-(tetrahydrofuran-2-ylmethyl)acetamide |
| STK869013 |
| NCGC00058009-02 |
| CCG-117342 |
| HMS2295O05 |
| AKOS022094082 |
| CHEMBL1421291 |
| Q27185930 |
| 2-(2-oxo-1-benzo[cd]indolyl)-n-(2-oxolanylmethyl)acetamide |
| 2-(2-oxobenzo[cd]indol-1-yl)-n-(oxolan-2-ylmethyl)acetamide |
| Class | Description |
|---|---|
| isoindoles | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.6310 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 0.6310 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 15.8114 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 31.6228 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 25.1189 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
| ClpP | Bacillus subtilis | Potency | 25.1189 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 112.2020 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| snurportin-1 | Homo sapiens (human) | Potency | 112.2020 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 22.3872 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 25.1189 | 0.0003 | 11.4484 | 31.6228 | AID900 |
| Caspase-7 | Homo sapiens (human) | Potency | 25.1189 | 3.9811 | 18.5856 | 31.6228 | AID889 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 0.8913 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| RNA binding | Caspase-7 | Homo sapiens (human) |
| aspartic-type endopeptidase activity | Caspase-7 | Homo sapiens (human) |
| cysteine-type endopeptidase activity | Caspase-7 | Homo sapiens (human) |
| protein binding | Caspase-7 | Homo sapiens (human) |
| peptidase activity | Caspase-7 | Homo sapiens (human) |
| cysteine-type peptidase activity | Caspase-7 | Homo sapiens (human) |
| cysteine-type endopeptidase activity involved in apoptotic process | Caspase-7 | Homo sapiens (human) |
| cysteine-type endopeptidase activity involved in execution phase of apoptosis | Caspase-7 | Homo sapiens (human) |
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular space | Caspase-7 | Homo sapiens (human) |
| nucleus | Caspase-7 | Homo sapiens (human) |
| cytoplasm | Caspase-7 | Homo sapiens (human) |
| cytosol | Caspase-7 | Homo sapiens (human) |
| nucleus | Caspase-7 | Homo sapiens (human) |
| nucleoplasm | Caspase-7 | Homo sapiens (human) |
| cytosol | Caspase-7 | Homo sapiens (human) |
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||